Clinical Trial Patient Screening via Genome Analysis


QIAGEN performs genome sequencing and analyzes the sequenced DNA to help identify patients who have variants of interest compared to a reference genome, and thus could have the protein that the cryo-EM and LAMMPS output have identified as being of interest. By speeding the identification of patients who have the right protein and thus meet the criteria for a clinical trial, this analysis can speed an important aspect of clinical trials, reduce trial costs, and lead to more effective targeted treatments with fewer undesirable side effects.

Product and Performance Information


Intel's compilers may or may not optimize to the same degree for non-Intel microprocessors for optimizations that are not unique to Intel microprocessors. These optimizations include SSE2, SSE3, and SSSE3 instruction sets and other optimizations. Intel does not guarantee the availability, functionality, or effectiveness of any optimization on microprocessors not manufactured by Intel. Microprocessor-dependent optimizations in this product are intended for use with Intel microprocessors. Certain optimizations not specific to Intel microarchitecture are reserved for Intel microprocessors. Please refer to the applicable product User and Reference Guides for more information regarding the specific instruction sets covered by this notice.

Notice revision #20110804